BOSTON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the
U.S. Food and Drug Administration (FDA) has approved KALYDECO®
(ivacaftor) for use in more than 600 people with cystic fibrosis (CF)
ages 2 and older who have one of five residual function mutations...

Boston Public High School Students Hannah Mei and Sayed Shah
Receive Vertex Science Leaders Scholarship to Pursue STEM Degrees at
UMass
BOSTON--(BUSINESS WIRE)--
Vertex,
Boston Public Schools (BPS) and the University of Massachusetts today
announced the recipients of the an...

BOSTON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second
quarter 2017 financial results on Wednesday, July 26, 2017 after the
financial markets close. The company will host a conference call and
webcast at 5:15 p.m. ET. To access the call, please dial (866) 501-...

- Effective immediately, agreement enables hundreds of people in
Italy to access this important medicine -
- Recent pricing and reimbursement agreements have enabled broad
access to ORKAMBI for thousands of eligible patients in multiple
European countries; negotiations continue in a number of othe...

BOSTON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
management will present at the Goldman Sachs Healthcare Conference on
Tuesday, June 13, 2017 at 12:20 p.m. ET.
Management's remarks will be available live through Vertex's website at www.vrtx...

- Presentation of data from a Phase 3 study of ORKAMBI in children
ages 6-11 with two copies of the F508del mutation demonstrated
improvements in lung function and sweat chloride; study also published
online in The Lancet Respiratory Medicine today -
- ECFS data presentations demonstrate that trea...

-Agreement provides access to ORKAMBI for people who have two copies
of the F508del mutation and expands access to KALYDECO for all eligible
patients-
LONDON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has
reached an agreement wit...

- New Program Helps CF Families Pursue Higher Education -
BOSTON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the
first recipients of the company's All in for CF Scholarship
program. Each of the 40 scholarship recipients will be awarded $5,00...

BOSTON--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
management will present at the UBS Healthcare Conference on Tuesday, May
23, 2017 at 11:00 a.m. ET.
Management's remarks will be available live through Vertex's website at www.vrtx.com
...

- Precision medicine decision based on in vitro data and supported by
more than five years of real-world clinical data that demonstrate
KALYDECO's strong safety and efficacy profile for eligible patients -
- Vertex working with FDA to obtain rapid approval for more than 600
additional people who h...

Third Annual CF "Circle of Care" Grants Connect CF Community Members
Around the World to Share Their Ideas and Inspiration
BOSTON--(BUSINESS WIRE)--
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the
grant recipients for its 2017 Cystic Fibrosis (CF) Circl...

The Science of Possibility

Vertex creates new possibilities in medicine to cure diseases and improve people's lives. We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.